Exosomes in Glioma: Integrating Molecular Mechanisms with Diagnostic and Therapeutic Potential
Source abstract
Abstract
ABSTRACT Glioma, a lethal intracranial malignancy with limited therapeutic options, represents one of oncology's most persistent challenges. Entering a new era of molecular oncology, exosomes—nanoscale extracellular vesicles—have emerged as master regulators of intercellular communication, dynamically sculpting the glioma tumor microenvironment (TME) and orchestrating hallmarks of malignancy, including immune evasion, angiogenesis, and therapeutic resistance. These versatile vesicles transport bioactive cargo (e.g., miRNAs, lncRNAs, proteins) to reprogram stromal, neuronal, and immune cells, creating a permissive niche for tumor progression. Recent breakthroughs now position exosomes at the forefront of translational medicine, serving dual roles as minimally invasive biomarkers and engineered nanovectors for precision therapy. This review systematically deciphers how exosomes fuel glioma pathogenesis—from driving macrophage polarization and T‐cell suppression to facilitating blood‐brain barrier disruption and chemoresistance. Beyond mechanistic insights, we spotlight pioneering strategies harnessing exosomes for drug delivery, immunotherapy, and nanotechnology‐driven interventions. By bridging foundational discoveries with clinical applications, this work heralds a new era in glioma management, where exosome‐based tools promise to revolutionize personalized diagnosis, prognostication, and therapeutic innovation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Glioma Diagnosis and Treatment · Neuroinflammation and Neurodegeneration Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery Xiangya Hospital Central South University Changsha China
Xiangya School of Medicine Central South University Changsha China
Department of Neurosurgery The Second Affiliated Hospital Chongqing Medical University Chongqing China
Western Institute of Digital‐Intelligent Medicine Chongqing China
Department of Breast and Thyroid Surgery The Second Affiliated Hospital Chongqing Medical University Chongqing China
College of Life Science and Technology Huazhong University of Science and Technology Wuhan China
Department of Neurology Hunan Aerospace Hospital Hunan Normal University Changsha China
Department of Neurosurgery Hunan University of Medicine General Hospital Huaihua China
Department of Oncology Zhujiang Hospital Southern Medical University Guangzhou China
Department of Neurosurgery Xiangya School of Medicine Central South University Changsha China
Department of Neurosurgery Xiangya Hospital Jiangxi. (National Regional Center for Neurological Diseases) Central South University Nanchang China
National Clinical Research Center for Geriatric Diseases (Xiangya Hospital) Central South University Changsha China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Chongqing Municipality · Beijing Xisike Clinical Oncology Research Foundation
References (100+)
Show source-provided references
1. 10.1093/neuonc/nou08710.1093/neuonc/nou087 ↗
2. 10.2217/fon-2021-096310.2217/fon-2021-0963 ↗
3. 10.1016/j.gene.2022.14621710.1016/j.gene.2022.146217 ↗
4. 10.3390/cells811142810.3390/cells8111428 ↗
5. 10.1517/13543784.2015.104833210.1517/13543784.2015.1048332 ↗
6. 10.1126/science.aau697710.1126/science.aau6977 ↗
7. 10.1002/adma.20180289610.1002/adma.201802896 ↗
8. 10.1194/jlr.R08434310.1194/jlr.R084343 ↗
9. 10.1016/j.cca.2019.02.02110.1016/j.cca.2019.02.021 ↗
10. 10.3389/fimmu.2021.81374710.3389/fimmu.2021.813747 ↗
11. 10.1016/j.celrep.2020.01.08910.1016/j.celrep.2020.01.089 ↗
12. 10.3390/ijms23241561210.3390/ijms232415612 ↗
13. 10.1016/j.bbrc.2018.05.14010.1016/j.bbrc.2018.05.140 ↗
14. 10.1186/s12987-019-0123-z10.1186/s12987-019-0123-z ↗
15. 10.1111/jnc.1510210.1111/jnc.15102 ↗
16. Exosomal lncRNA‑ATB Activates Astrocytes That Promote Glioma Cell Invasion
17. 10.1615/JEnvironPatholToxicolOncol.202103977510.1615/JEnvironPatholToxicolOncol.2021039775 ↗
18. 10.1371/journal.pone.023461410.1371/journal.pone.0234614 ↗
19. 10.1038/s41582-018-0025-810.1038/s41582-018-0025-8 ↗
20. 10.1038/s41419-022-05144-610.1038/s41419-022-05144-6 ↗
21. 10.1152/physrev.00006.201710.1152/physrev.00006.2017 ↗
22. 10.3390/antiox1107122510.3390/antiox11071225 ↗
23. 10.1016/j.cell.2022.06.05410.1016/j.cell.2022.06.054 ↗
24. 10.1186/s13287-018-1049-010.1186/s13287-018-1049-0 ↗
25. 10.4149/neo_2016_61110.4149/neo_2016_611 ↗
26. 10.1186/s12885-019-6460-010.1186/s12885-019-6460-0 ↗
27. 10.1158/0008-5472.CAN-16-252410.1158/0008-5472.CAN-16-2524 ↗
28. 10.1016/j.biopha.2019.10862510.1016/j.biopha.2019.108625 ↗
29. hUC‐MSCs Secreted Exosomes Inhibit the Glioma Cell Progression through PTENP1/miR‐10a‐5p/PTEN Pathway
30. 10.1080/2162402X.2021.196531710.1080/2162402X.2021.1965317 ↗
31. 10.1002/glia.2283610.1002/glia.22836 ↗
32. 10.1016/j.tins.2020.10.01410.1016/j.tins.2020.10.014 ↗
33. 10.1016/j.bbrc.2019.08.05710.1016/j.bbrc.2019.08.057 ↗
34. 10.1016/j.canlet.2018.06.04110.1016/j.canlet.2018.06.041 ↗
35. 10.1016/j.celrep.2021.10882910.1016/j.celrep.2021.108829 ↗
36. 10.3390/ijms2111399010.3390/ijms21113990 ↗
37. 10.1038/nn.418510.1038/nn.4185 ↗
38. 10.1186/s12967-021-02766-w10.1186/s12967-021-02766-w ↗
39. 10.1038/s41419-022-04908-410.1038/s41419-022-04908-4 ↗
40. 10.1002/term.324410.1002/term.3244 ↗
41. 10.1038/s41467-022-33235-710.1038/s41467-022-33235-7 ↗
42. 10.1158/0008-5472.CAN-23-060910.1158/0008-5472.CAN-23-0609 ↗
43. 10.1186/s13046-020-01810-910.1186/s13046-020-01810-9 ↗
44. 10.1186/s13046-019-1078-210.1186/s13046-019-1078-2 ↗
45. 10.1093/jnen/nlaa04110.1093/jnen/nlaa041 ↗
46. 10.1007/s12264-020-00626-z10.1007/s12264-020-00626-z ↗
47. 10.1002/ijc.2965810.1002/ijc.29658 ↗
48. 10.3390/ijms2016398210.3390/ijms20163982 ↗
49. 10.1080/2162402X.2018.147864710.1080/2162402X.2018.1478647 ↗
50. 10.1016/j.coph.2020.07.00110.1016/j.coph.2020.07.001 ↗
51. 10.1038/s41419-021-04359-310.1038/s41419-021-04359-3 ↗
52. 10.1038/s41388-019-0996-y10.1038/s41388-019-0996-y ↗
53. 10.1038/s41419-021-03664-110.1038/s41419-021-03664-1 ↗
54. 10.1038/s41388-022-02457-w10.1038/s41388-022-02457-w ↗
55. 10.1007/s10565-021-09652-710.1007/s10565-021-09652-7 ↗
56. 10.1016/j.intimp.2021.10793310.1016/j.intimp.2021.107933 ↗
57. 10.1016/j.cellimm.2021.10441910.1016/j.cellimm.2021.104419 ↗
58. 10.1038/s41419-020-03042-310.1038/s41419-020-03042-3 ↗
59. 10.1080/20013078.2019.164899510.1080/20013078.2019.1648995 ↗
60. 10.1089/ten.tea.2016.050810.1089/ten.tea.2016.0508 ↗
61. 10.1038/s41388-022-02360-410.1038/s41388-022-02360-4 ↗
62. 10.3390/ijms2215824810.3390/ijms22158248 ↗
63. 10.1111/cas.1498410.1111/cas.14984 ↗
64. 10.1158/2326-6066.CIR-21-025810.1158/2326-6066.CIR-21-0258 ↗
65. 10.1038/s41419-022-05056-510.1038/s41419-022-05056-5 ↗
66. AHIF Promotes Glioblastoma Progression and Radioresistance via Exosomes
67. 10.1093/neuonc/noae06810.1093/neuonc/noae068 ↗
68. 10.1093/neuonc/noz15710.1093/neuonc/noz157 ↗
69. 10.1007/s11060-017-2680-910.1007/s11060-017-2680-9 ↗
70. 10.1016/j.jaci.2006.06.04110.1016/j.jaci.2006.06.041 ↗
71. 10.1038/s41467-017-01392-910.1038/s41467-017-01392-9 ↗
72. 10.1016/j.actbio.2017.06.00210.1016/j.actbio.2017.06.002 ↗
73. 10.7150/thno.2295210.7150/thno.22952 ↗
74. 10.7150/thno.7176310.7150/thno.71763 ↗
75. 10.1186/s12964-022-00996-z10.1186/s12964-022-00996-z ↗
76. 10.1158/0008-5472.CAN-15-101110.1158/0008-5472.CAN-15-1011 ↗
77. 10.1007/s11064-022-03629-610.1007/s11064-022-03629-6 ↗
78. 10.1016/j.febslet.2009.07.05810.1016/j.febslet.2009.07.058 ↗
79. 10.1002/stem.239310.1002/stem.2393 ↗
80. 10.1038/ncb322210.1038/ncb3222 ↗
81. 10.1093/neuonc/nox08510.1093/neuonc/nox085 ↗
82. 10.1074/mcp.RA118.00064410.1074/mcp.RA118.000644 ↗
83. 10.1126/sciadv.aaz611910.1126/sciadv.aaz6119 ↗
84. 10.1016/j.bios.2021.11347610.1016/j.bios.2021.113476 ↗
85. 10.1016/j.ymthe.2019.07.01110.1016/j.ymthe.2019.07.011 ↗
86. 10.1007/s13402-017-0355-310.1007/s13402-017-0355-3 ↗
87. Exosomal microRNA‐210 Is a Potentially Non‐invasive Biomarker for the Diagnosis and Prognosis of Glioma
88. 10.1002/ijc.3120910.1002/ijc.31209 ↗
89. 10.1016/j.clineuro.2019.10565210.1016/j.clineuro.2019.105652 ↗
90. 10.1038/ncomms1444810.1038/ncomms14448 ↗
91. 10.1038/s41374-020-00522-010.1038/s41374-020-00522-0 ↗
92. 10.1016/j.ymthe.2021.06.02310.1016/j.ymthe.2021.06.023 ↗
93. 10.1158/1535-7163.MCT-18-072510.1158/1535-7163.MCT-18-0725 ↗
94. 10.1038/s41467-020-17717-010.1038/s41467-020-17717-0 ↗
95. 10.1093/clinchem/hvab25410.1093/clinchem/hvab254 ↗
96. 10.1186/s12943-021-01485-610.1186/s12943-021-01485-6 ↗
97. 10.1002/iub.238310.1002/iub.2383 ↗
98. 10.1016/j.devcel.2021.12.00710.1016/j.devcel.2021.12.007 ↗
99. 10.1158/0008-5472.CAN-20-227010.1158/0008-5472.CAN-20-2270 ↗
100. 10.1186/s12935-024-03522-y10.1186/s12935-024-03522-y ↗